CGMs Improve Blood Sugar for Type 2 Diabetes Patients

AURORA, Colo., Oct. 14, 2026 /CourierPR/ -- A new large-scale clinical trial has provided the strongest evidence yet that continuous glucose monitors (CGMs) can significantly improve blood sugar in people with type 2 diabetes who are not using insulin, according to findings published in the New England Journal of Medicine. The study, which included 283 adults across 22 U.S. primary care practices, found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared to those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study’s findings, which were led by Tamara Oser, MD, a professor in the University of Colorado Anschutz Department of Family Medicine, suggest that CGMs could transform diabetes management for millions of Americans with type 2 diabetes who do not use insulin. Currently, the American Diabetes Association’s Standards of Care cite Level A evidence, the highest rating supported by rigorous clinical research, for CGM use in patients receiving insulin. However, recommendations for people with diabetes who do not take insulin are supported by Level C evidence, reflecting more limited research.

The researchers hope these new findings could help strengthen national diabetes care guidelines and expand insurance coverage, making this technology more accessible to the millions of patients who could benefit from it.

The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared to those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes. The study, which included 283 adults across 22 U.S. primary care practices, found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared to those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

The study, the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGMs in adults with type 2 diabetes who do not take insulin, found that CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months.